Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist in vitro.
Description | Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist in vitro. |
Targets&IC50 | TrkC:0.85 nM, TrkA:0.85 nM, MET Y1230C:0.37 nM, MET Y1230C:1.2 nM, MET D1228N:1.3 nM |
Synonyms | DCC-2701 |
Molecular Weight | 510.473 |
Formula | C26H21F3N4O4 |
CAS No. | 1345847-93-9 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 10 mM
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Altiratinib 1345847-93-9 蛋白酪氨酸激酶 血管生成 c-Met/HGFR FLT Tie-2 Trk receptor VEGFR Cluster of differentiation antigen 135 DCC 2701 Trk Receptor Inhibitor CD135 inhibit FLT3 Vascular endothelial growth factor receptor Tropomyosin related kinase receptor DCC-2701 DCC2701 Fms like tyrosine kinase 3 inhibitor